Comparative bioavailability and tolerability study of two intramuscular formulations of thiocolchicoside in healthy volunteers

Mauro Paolo Ferrari, G. Gatti, C. Fattore, G. Fedele, R. Novellini

Research output: Contribution to journalArticle

Abstract

The comparative bioavailability and tolerability of two intramuscular formulations of thiocolchicoside (test, Thiocolchicoside, 4 mg ampoules, Dompé S.p.A.; reference, Muscoril®, 4 mg ampoules, Inverni della Beffa S.p.A.) were investigated in twelve healthy volunteers according to a single dose (4 rog), cross-over, randomized design. Plasma thiocolchicoside concentrations were determined by using a validated specific HPLC/MS assay and local tolerability was investigated by assessing subjective pain intensity on a visual analogue scale (VAS), reddening at the injection site, and plasma creatinine phosphokinase (CPK) levels. Pharmacokinetic parameters after administration of the test formulation were similar to those observed after administration of the reference (Tmax 0.50 (0.25-1.00) vs 0.50 (0.25-1.00), median and range; Cmax 115.5 ± 26.6 vs 113.2 ± 40.4 ng/ml; AUC 291.6 ± 77.7 vs 283.3 ± 98.9 ng.h/ml, means ± SD). Relative bioavailability (F) was 1.05 ± 0.13. Statistical comparison of pain intensity, CPK levels and occurrence of redness at the injection site did not show statistically significant differences between formulations. It is concluded that the investigated test formulation is bioequivalent and equally well tolerated as the marketed reference formulation.

Original languageEnglish
Pages (from-to)257-262
Number of pages6
JournalEuropean Journal of Drug Metabolism and Pharmacokinetics
Volume26
Issue number4
Publication statusPublished - 2001

Fingerprint

Biological Availability
Healthy Volunteers
Creatinine
Phosphotransferases
Pain
Injections
Visual Analog Scale
Cross-Over Studies
Area Under Curve
Pharmacokinetics
High Pressure Liquid Chromatography
thiocolchicoside

Keywords

  • Bioequivalence
  • Intramuscular bioavailability
  • Pharmacokinetics
  • Thiocolchicoside
  • Tolerability

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Comparative bioavailability and tolerability study of two intramuscular formulations of thiocolchicoside in healthy volunteers. / Ferrari, Mauro Paolo; Gatti, G.; Fattore, C.; Fedele, G.; Novellini, R.

In: European Journal of Drug Metabolism and Pharmacokinetics, Vol. 26, No. 4, 2001, p. 257-262.

Research output: Contribution to journalArticle

@article{158e89c6ee264aae80069e28c471fd99,
title = "Comparative bioavailability and tolerability study of two intramuscular formulations of thiocolchicoside in healthy volunteers",
abstract = "The comparative bioavailability and tolerability of two intramuscular formulations of thiocolchicoside (test, Thiocolchicoside, 4 mg ampoules, Domp{\'e} S.p.A.; reference, Muscoril{\circledR}, 4 mg ampoules, Inverni della Beffa S.p.A.) were investigated in twelve healthy volunteers according to a single dose (4 rog), cross-over, randomized design. Plasma thiocolchicoside concentrations were determined by using a validated specific HPLC/MS assay and local tolerability was investigated by assessing subjective pain intensity on a visual analogue scale (VAS), reddening at the injection site, and plasma creatinine phosphokinase (CPK) levels. Pharmacokinetic parameters after administration of the test formulation were similar to those observed after administration of the reference (Tmax 0.50 (0.25-1.00) vs 0.50 (0.25-1.00), median and range; Cmax 115.5 ± 26.6 vs 113.2 ± 40.4 ng/ml; AUC 291.6 ± 77.7 vs 283.3 ± 98.9 ng.h/ml, means ± SD). Relative bioavailability (F) was 1.05 ± 0.13. Statistical comparison of pain intensity, CPK levels and occurrence of redness at the injection site did not show statistically significant differences between formulations. It is concluded that the investigated test formulation is bioequivalent and equally well tolerated as the marketed reference formulation.",
keywords = "Bioequivalence, Intramuscular bioavailability, Pharmacokinetics, Thiocolchicoside, Tolerability",
author = "Ferrari, {Mauro Paolo} and G. Gatti and C. Fattore and G. Fedele and R. Novellini",
year = "2001",
language = "English",
volume = "26",
pages = "257--262",
journal = "European Journal of Drug Metabolism and Pharmacokinetics",
issn = "0378-7966",
publisher = "Springer Paris",
number = "4",

}

TY - JOUR

T1 - Comparative bioavailability and tolerability study of two intramuscular formulations of thiocolchicoside in healthy volunteers

AU - Ferrari, Mauro Paolo

AU - Gatti, G.

AU - Fattore, C.

AU - Fedele, G.

AU - Novellini, R.

PY - 2001

Y1 - 2001

N2 - The comparative bioavailability and tolerability of two intramuscular formulations of thiocolchicoside (test, Thiocolchicoside, 4 mg ampoules, Dompé S.p.A.; reference, Muscoril®, 4 mg ampoules, Inverni della Beffa S.p.A.) were investigated in twelve healthy volunteers according to a single dose (4 rog), cross-over, randomized design. Plasma thiocolchicoside concentrations were determined by using a validated specific HPLC/MS assay and local tolerability was investigated by assessing subjective pain intensity on a visual analogue scale (VAS), reddening at the injection site, and plasma creatinine phosphokinase (CPK) levels. Pharmacokinetic parameters after administration of the test formulation were similar to those observed after administration of the reference (Tmax 0.50 (0.25-1.00) vs 0.50 (0.25-1.00), median and range; Cmax 115.5 ± 26.6 vs 113.2 ± 40.4 ng/ml; AUC 291.6 ± 77.7 vs 283.3 ± 98.9 ng.h/ml, means ± SD). Relative bioavailability (F) was 1.05 ± 0.13. Statistical comparison of pain intensity, CPK levels and occurrence of redness at the injection site did not show statistically significant differences between formulations. It is concluded that the investigated test formulation is bioequivalent and equally well tolerated as the marketed reference formulation.

AB - The comparative bioavailability and tolerability of two intramuscular formulations of thiocolchicoside (test, Thiocolchicoside, 4 mg ampoules, Dompé S.p.A.; reference, Muscoril®, 4 mg ampoules, Inverni della Beffa S.p.A.) were investigated in twelve healthy volunteers according to a single dose (4 rog), cross-over, randomized design. Plasma thiocolchicoside concentrations were determined by using a validated specific HPLC/MS assay and local tolerability was investigated by assessing subjective pain intensity on a visual analogue scale (VAS), reddening at the injection site, and plasma creatinine phosphokinase (CPK) levels. Pharmacokinetic parameters after administration of the test formulation were similar to those observed after administration of the reference (Tmax 0.50 (0.25-1.00) vs 0.50 (0.25-1.00), median and range; Cmax 115.5 ± 26.6 vs 113.2 ± 40.4 ng/ml; AUC 291.6 ± 77.7 vs 283.3 ± 98.9 ng.h/ml, means ± SD). Relative bioavailability (F) was 1.05 ± 0.13. Statistical comparison of pain intensity, CPK levels and occurrence of redness at the injection site did not show statistically significant differences between formulations. It is concluded that the investigated test formulation is bioequivalent and equally well tolerated as the marketed reference formulation.

KW - Bioequivalence

KW - Intramuscular bioavailability

KW - Pharmacokinetics

KW - Thiocolchicoside

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=0035682773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035682773&partnerID=8YFLogxK

M3 - Article

C2 - 11808868

AN - SCOPUS:0035682773

VL - 26

SP - 257

EP - 262

JO - European Journal of Drug Metabolism and Pharmacokinetics

JF - European Journal of Drug Metabolism and Pharmacokinetics

SN - 0378-7966

IS - 4

ER -